Global Cancer Immunotherapy Market: Snapshot

The global cancer immunotherapy market is prognosticated to encounter a high rate of development over the coming years, inferable from the rise in number of people suffering from different types of cancers. In 2015, the global cancer immunotherapy market was esteemed at US$37.50 bn. its revenue is anticipated to progress at an extremely solid CAGR of 14.6% inside a conjecture period from 2016 to 2024, the global cancer immunotherapy market is required to achieve US$124.88 bn before the finish of 2024.

cancer immunotherapy market

Increased Efficiency Over Traditional Methods to Bolster Market Growth

As far as the treatment choices for cancer are concerned, cancer immunotherapy is foreseen to make genuine progress because of its greater efficiency over traditional treatment technique. The market is anticipated to demonstrate a high development rate over the upcoming years as well, because of an extremely promising treatment methods in the pipelines. In any case, the global cancer immunotherapy market is expected to be hindered by factors, for example, the increased level of steady loss inside the development cycles of its various product types, and overall absence of awareness about immunotherapy as a superior choice to conventional treatment in numerous regions of the world.

Cost-Effective Nature of Treatment Makes it Popular Among Patients

In terms of types of therapies, the global cancer immunotherapy market can be segmented into immune system modulators, immune checkpoint inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. Among these, monoclonal antibodies have so far been the leading choice of treatment methods for a large segment of the global healthcare industry, giving it a high lead over other segments. This therapy type has been more affordable than the other types, allowing it to gain greater popularity. However, the global cancer immunotherapy market is expected to witness a spike in the demand for immune checkpoint inhibitors due to their greater percentages of success rates and higher overall efficiency.

In terms of area of therapy, the global cancer immunotherapy market is divided into blood cancer, prostate cancer, melanoma, breast cancer, lung cancer, colorectal cancer, and other minor areas. Of these, breast cancer has been the leading area of immunotherapy. Lung cancer is also showing a very high increase in rate of demand owing to the growing population of smokers and the higher overall air pollution in urban areas.

Rising Awareness Among People to Fuel Growth in Europe

Geography-wise, the global cancer immunotherapy market is divided into Europe, North America, Asia Pacific, and rest of the world. The market's past has pretty much been established inside the created economies of the world. Europe and North America have been a base for a few of the best level innovative work in the global cancer immunotherapy market up until this point. The two regions have likewise represented a lot of demand for cancer immunotherapy inferable from a more awareness in population and improved healthcare care, globally.

The key players operating in the global cancer immunotherapy market are Amgen, Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline Plc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sanofi, Janssen Biotech, Inc., Merck & Co., Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Novartis AG, and Takeda Pharmaceuticals.

Strategies in Cancer Immunotherapy Market Expand Canvas for Oncology Personalized Medicine

Strides in cancer immunotherapy have redefined the standard of care in relation to both survival rates and quality of life. Immune checkpoint inhibitors and T lymphocytes overcome the traditional approaches to cancer therapies such as chemotherapy, radiation, and surgery. A growing understanding of cancer immunology, particularly how effector T cells recognize tumor antigens, is the key underpinning for this. Tumor immune evasion comprises, inter alia, different ways for T cell exhaustion; hence, ongoing research efforts focus on new strategies of immunotherapy that can counteract cancer immune evasion. New directions in the cancer immunotherapy market have stemmed from immune checkpoint inhibitors. In recent years, CTLA-4 and PD-1 have become T cell immune checkpoints of interest, and are expected to transform the standard of care in cancer immunotherapy. However, current approaches in cancer immunotherapy are still in preliminary stages, due to recalcitrant nature of immune-related adverse events. These events pose substantial challenges in predicting, diagnosing, and treating cancer types. Such events have been observed notably in melanoma and lung cancer. This is despite the fact that a number of molecular therapies have been approved by the FDA. Another rapidly emerging development avenue likely to attract lodes of investments in the cancer immunotherapy market is vaccination therapy. However, their role in preventing cancer is debatable and lacks evidence, which implies they are largely therapeutic.

The currently emerging coronavirus pandemic caused by SARS-CoV-2 has posed serious and unprecedented threats to public health across the world. Capable of rapid transmission, it has resulted in massive mortality and morbidity. Several restrictions have been imposed by governments to prevent the spread of the virus, thereby, crippling economic activities on various levels. Numerous non-essential economic activities and firm production have suffered. As a fallout, several businesses from across different industries were forced to shift to new business models, notably digital models and industrial automation, to keep them afloat. New agile models have gained attention by contract research organizations, research community, and lifesciences industries in major economies of the world. All these are shaping the contours of the market dynamics in the post-pandemic world.

Global Cancer Immunotherapy Market: Overview 

The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments. This has pushed the growth of the global cancer immunotherapy therapy. As immunotherapy therapy has a higher success rate and proven efficiency over conventional treatment methods for cancer, its demand is higher and therefore, the market is expected to witness a remarkable growth over the coming years. The treatment pipeline looks promising and is thus, expected to ensure a healthy growth of the market. 

The report offers forecasts of the overall cancer immunotherapy market over the global level as well as on regional levels. The estimated size of each of the segments and sub-segments has also been given in the report. Macroeconomic indicators, drivers, and restraints impacting the global cancer immunotherapy market have been included along with their impact on each region. Current challenges met by players in the cancer immunotherapy market have been elaborated on, thus giving a brief idea to readers and investors the problems they may encounter while investing in the competitive market. 

Global Cancer Immunotherapy Market: Trends and Drivers 

The global cancer immunotherapy market is expected to hold promising growth as there lies immense scope for improvement and development. The increasing number of clinical trials held particularly in immunotherapy is expected to boost the market’s growth. With the recognition from various medical bodies as the foremost line of therapy over conventional chemotherapy, cancer immunotherapy is estimated to hold immense potential and growth opportunity in the coming years. 

However, factors such as high attrition rates during product development phase are anticipated to restrict the growth of the market. Also, an overall lack of awareness about immunotherapy being a better treatment option will impede the growth of the market. The high cost of clinical trials poses a challenge for players in the market. With many types and subtypes of cancer, having a single mode of treatment method is impossible, increasing the attrition rates of new drugs and treatments. Only a handful of contenders in the pipeline pass through the phase III trials and the rest are considered to be inefficient. This is yet another challenge faced by players in the market. 

Global Cancer Immunotherapy Market: Segmentation 

On the basis of therapeutic area, the market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. By end users, the global cancer immunotherapy market is segmented into ASC’s (ambulatory surgical centers), hospitals, clinics, and cancer research centers. Hospitals are expected to be the leading segment in the market. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Asia Pacific is poised to witness significant growth in the market.

Key Players Mentioned in this Report are: 

The report provides studies key players operating in the market. Some of the key players in the global cancer immunotherapy market are: F.Hoffmann-La Roche Ltd., AstraZenca Plc, Eli Lilly and Company, Amgen, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Novartis AG, Pfizer, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Janssen Biotech, Inc., Merck & Co., Inc., Sanofi, Takeda Pharmaceuticals, and Spectrum Pharmaceuticals, Inc. 

The report segments the global cancer immunotherapy market as: 

By Geography: 

  • North America
  • Asia Pacific
  • Europe
  • Rest of the World 

This report gives you access to decisive data such as: 

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report 

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cancer Immunotherapy Market

4. Market Overview
     4.1. Introduction
            4.1.1. Market Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Product/Therapeutic Area Specific
            4.3.3. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
            4.4.4. Trends
     4.5. Global Cancer Immunotherapy Market Analysis and Forecasts, 2016–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Cancer Immunotherapy Market - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
            4.8.1. List of active market participants
                     4.8.1.1.  Manufacturers
                     4.8.1.2.  Distributors
            4.8.2. Forward – Backward Integration Scenario
     4.9. Market Outlook
     4.10. Pipeline Snapshot
     4.11. Cancer Epidemiology
     4.12. Reimbursement Scenario and Patient Support Programs Overview

5. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapy Type
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Market Value Forecast By Therapy Type, 2016–2024
            5.3.1. Monoclonal Antibodies
            5.3.2. Immune Checkpoint Inhibitors
                     5.3.2.1. PD-1/PD-L1
                     5.3.2.2. CTLA-4
            5.3.3. Immune System Modulators
            5.3.4. Cancer Vaccines
            5.3.5. Others
     5.4. Market Attractiveness By Therapy 

6. Global Cancer Immunotherapy Market Analysis and Forecasts, By End User 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value  Forecast By End User, 2016–2024
            6.3.1. Hospitals
            6.3.2. ASC's
            6.3.3. Cancer Research Institutes
            6.3.4. Clinics
     6.4. Market Attractiveness By End User 

7. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapeutic Area 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value  Forecast By Therapeutic Area, 2016–2024
            7.3.1. Lung Cancer
            7.3.2. Colorectal Cancer
            7.3.3. Breast Cancer
            7.3.4. Prostate Cancer
            7.3.5. Melanoma
            7.3.6. Blood Cancers
            7.3.7. Others
     7.4. Market Attractiveness By Therapeutic Area 

8. Global Cancer Immunotherapy Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value  Forecast By Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America 
            8.3.5. Middle East and Africa 
     8.4. Market Attractiveness By Region

9. North America Cancer Immunotherapy Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
     9.2. Market Value Forecast By Therapy Type, 2016–2024
            9.2.1. Monoclonal Antibodies
            9.2.2. Immune Checkpoint Inhibitors
                     9.2.2.1. PD-1/PD-L1
                     9.2.2.2. CTLA-4
            9.2.3. Immune System Modulators
            9.2.4. Cancer Vaccines
            9.2.5. Others
     9.3. Market Value  Forecast By End User, 2016–2024
            9.3.1. Hospitals
            9.3.2. ASC's
            9.3.3. Cancer Research Institutes
            9.3.4. Clinics
     9.4. Market Value  Forecast By Therapeutic Area, 2016–2024
            9.4.1. Lung Cancer
            9.4.2. Colorectal Cancer
            9.4.3. Breast Cancer
            9.4.4. Prostate Cancer
            9.4.5. Melanoma
            9.4.6. Blood Cancer
            9.4.7. Others
     9.5. Market Value  Forecast By Country, 2016–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Therapy Type
            9.6.2. By End User 
            9.6.3. By Therapeutic Area 
            9.6.4. By Country

10. Europe Cancer Immunotherapy Market Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
     10.2.Market Value  Forecast By Therapy Type, 2016–2024
            10.2.1. Monoclonal Antibodies
            10.2.2. Immune Checkpoint Inhibitors
                     10.2.2.1. PD-1/PD-L1
                     10.2.2.2. CTLA-4
            10.2.3. Immune System Modulators
            10.2.4. Cancer Vaccines
            10.2.5. Others
     10.3.Market Value  Forecast By End User, 2016–2024
            10.3.1. Hospitals
            10.3.2. ASC's
            10.3.3. Cancer Research Institutes
            10.3.4. Clinics
     10.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            10.4.1. Lung Cancer
            10.4.2. Colorectal Cancer
            10.4.3. Breast Cancer
            10.4.4. Prostate Cancer
            10.4.5. Melanoma
            10.4.6. Blood Cancer
            10.4.7. Others
     10.5.Market Value  Forecast By Country, 2016–2024
            10.5.1. Germany
            10.5.2. U.K. 
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe
     10.6.Market Attractiveness Analysis 
            10.6.1. By Therapy Type
            10.6.2. By End User 
            10.6.3. By Therapeutic Area 
            10.6.4. By Country

11. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
     11.2.Market Value  Forecast By Therapy Type, 2016–2024
            11.2.1. Monoclonal Antibodies
            11.2.2. Immune Checkpoint Inhibitors
                     11.2.2.1. PD-1/PD-L1
                     11.2.2.2. CTLA-4
            11.2.3. Immune System Modulators
            11.2.4. Cancer Vaccines
            11.2.5. Others
     11.3.Market Value  Forecast By End User, 2016–2024
            11.3.1. Hospitals
            11.3.2. ASC's
            11.3.3. Cancer Research Institutes
            11.3.4. Clinics
     11.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            11.4.1. Lung Cancer
            11.4.2. Colorectal Cancer
            11.4.3. Breast Cancer
            11.4.4. Prostate Cancer
            11.4.5. Melanoma
            11.4.6. Blood Cancer
            11.4.7. Others
     11.5.Market Value  Forecast By Country, 2016–2024
            11.5.1. Japan
            11.5.2. China
            11.5.3. India
            11.5.4. Australia
            11.5.5. New Zealand
            11.5.6. Rest of APAC
     11.6.Market Attractiveness Analysis 
            11.6.1. By Therapy Type
            11.6.2. By End User 
            11.6.3. By Therapeutic Area 
            11.6.4. By Country
12. Latin America Cancer Immunotherapy Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
     12.2.Market Value  Forecast By Therapy Type, 2016–2024
            12.2.1. Monoclonal Antibodies
            12.2.2. Immune Checkpoint Inhibitors
                     12.2.2.1. PD-1/PD-L1
                     12.2.2.2. CTLA-4
            12.2.3. Immune System Modulators
            12.2.4. Cancer Vaccines
            12.2.5. Others
     12.3.Market Value  Forecast By End User, 2016–2024
            12.3.1. Hospitals
            12.3.2. ASC's
            12.3.3. Cancer Research Institutes
            12.3.4. Clinics
     12.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            12.4.1. Lung Cancer
            12.4.2. Colorectal Cancer
            12.4.3. Breast Cancer
            12.4.4. Prostate Cancer
            12.4.5. Melanoma
            12.4.6. Blood Cancer
            12.4.7. Others
     12.5.Market Value  Forecast By Country, 2016–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6.Market Attractiveness Analysis 
            12.6.1. By Therapy Type
            12.6.2. By End User 
            12.6.3. By Therapeutic Area 
            12.6.4. By Country

13. Middle East and Africa Cancer Immunotherapy Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
     13.2.Market Value  Forecast By Therapy Type, 2016–2024
            13.2.1. Monoclonal Antibodies
            13.2.2. Immune Checkpoint Inhibitors
                     13.2.2.1. PD-1/PD-L1
                     13.2.2.2. CTLA-4
            13.2.3. Immune System Modulators
            13.2.4. Cancer Vaccines
            13.2.5. Others
     13.3.Market Value  Forecast By End User, 2016–2024
            13.3.1. Hospitals
            13.3.2. ASC's
            13.3.3. Cancer Research Institutes
            13.3.4. Clinics
     13.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            13.4.1. Lung Cancer
            13.4.2. Colorectal Cancer
            13.4.3. Breast Cancer
            13.4.4. Prostate Cancer
            13.4.5. Melanoma
            13.4.6. Blood Cancer
            13.4.7. Others
     13.5.Market Value  Forecast By Country, 2016–2024
            13.5.1. Saudi Arabia
            13.5.2. UAE
            13.5.3. South Africa
            13.5.4. Rest of MEA
     13.6.Market Attractiveness Analysis 
            13.6.1. By Therapy Type
            13.6.2. By End User 
            13.6.3. By Therapeutic Area 
            13.6.4. By Country

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2015)
     14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. Amgen, Inc.
                     14.3.1.1. Overview
                     14.3.1.2. Financials
                     14.3.1.3. Recent Developments
                     14.3.1.4. Strategy 
            14.3.2. AstraZenca Plc
                     14.3.2.1. Overview
                     14.3.2.2. Financials
                     14.3.2.3. Recent Developments
                     14.3.2.4. Strategy
            14.3.3. Bristol-Myers Squibb Company
                     14.3.3.1. Overview
                     14.3.3.2. Financials
                     14.3.3.3. Recent Developments
                     14.3.3.4. Strategy
            14.3.4. Eli Lilly and Company
                     14.3.4.1. Overview
                     14.3.4.2. Financials
                     14.3.4.3. Recent Developments
                     14.3.4.4. Strategy
            14.3.5. F.Hoffmann-La Roche Ltd.
                     14.3.5.1. Overview
                     14.3.5.2. Financials
                     14.3.5.3. Recent Developments
                     14.3.5.4. Strategy
            14.3.6. GlaxoSmithKline Plc.
                     14.3.6.1. Overview
                     14.3.6.2. Financials
                     14.3.6.3. Recent Developments
                     14.3.6.4. Strategy
            14.3.7. Janssen Biotech, Inc.
                     14.3.7.1. Overview
                     14.3.7.2. Financials
                     14.3.7.3. Recent Developments
                     14.3.7.4. Strategy
            14.3.8. Merck & Co.
                     14.3.8.1. Overview
                     14.3.8.2. Financials
                     14.3.8.3. Recent Developments
                     14.3.8.4. Strategy
            14.3.9. Novartis AG
                     14.3.9.1. Overview
                     14.3.9.2. Financials
                     14.3.9.3. Recent Developments
                     14.3.9.4. Strategy
            14.3.10. Pfizer, Inc.
                     14.3.10.1. Overview
                     14.3.10.2. Financials
                     14.3.10.3. Recent Developments
                     14.3.10.4. Strategy
            14.3.11. Sanofi
                     14.3.11.1. Overview
                     14.3.11.2. Financials
                     14.3.11.3. Recent Developments
                     14.3.11.4. Strategy
            14.3.12. Spectrum Pharmaceuticals, Inc.
                     14.3.12.1. Overview
                     14.3.12.2. Financials
                     14.3.12.3. Recent Developments
                     14.3.12.4. Strategy
            14.3.13. Takeda Pharmaceuticals
                     14.3.13.1. Overview
                     14.3.13.2. Financials
                     14.3.13.3. Recent Developments
                     14.3.13.4. Strategy

List of Tables

Table 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 2: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, By Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 3: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 4: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 5: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 6: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 7: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 8: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 9: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 10: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 12: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 13: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 14: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 15: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 16: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 17: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 18: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 19: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 20: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 21: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 22: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 23: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 24: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 25: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 26: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 27: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 28: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 29: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 30: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024

List of Figures

Figure 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2015–2024
Figure 2: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 3: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Monoclonal Antibodies, 2016–2024
Figure 4: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune Checkpoint Inhibitors, 2016–2024 
Figure 5: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune System Modulators, 2016–2024
Figure 6: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Vaccines, 2016–2024 
Figure 7: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Others, 2016–2024
Figure 8: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type
Figure 9: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By PD-1/PD-L1 Type, 2016–2024
Figure 10: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By CTLA-4 Type, 2016–2024 
Figure 11: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type (Immune Checkpoint Inhibitors)
Figure 12: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 13: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area
Figure 14: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Lung Cancer, 2016–2024
Figure 15: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Colorectal Cancer, 2016–2024 
Figure 16: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Breast Cancer, 2016–2024
Figure 17: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Prostate Cancer, 2016–2024
Figure 18: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Melanoma, 2016–2024
Figure 19: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Blood Cancers, 2016–2024 
Figure 20: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Other Cancers, 2016–2024
Figure 21: Global Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 22: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Hospitals, 2016–2024
Figure 23: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By ASC’s, 2016–2024
Figure 24: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Research Institutes, 2016–2024
Figure 25: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Clinics, 2016–2024 
Figure 26: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-User
Figure 27: Global Cancer Immunotherapy Market Value Share Analysis, by Region, 2016 and 2024
Figure 28: Global Cancer Immunotherapy Market Attractiveness Analysis, by Region
Figure 29: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 30: North America Cancer Immunotherapy Market Attractiveness Analysis By Country
Figure 31: North America Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 32: North America Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 33: North America Market Value Share Analysis, by End-User, 2016 and 2024
Figure 34: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: U.S. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 36: U.S. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 37: Canada Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 38: Canada Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 39: North America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 40: North America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 41: North America Cancer Immunotherapy Market Attractiveness by End-User
Figure 42: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 43: Europe Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 44: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 45: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 46: Europe Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 47: Europe Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 48: Germany Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 49: Germany Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 50: U.K. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 51: U.K. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 52: France Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 53: France Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 54: Spain Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 55: Spain Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 56: Italy Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 57: Italy Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 58: Rest of Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 59: Rest of Europe Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 60: Europe Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 61: Europe Cancer Immunotherapy Market Attractiveness by Therapeutic Area 
Figure 62: Europe Cancer Immunotherapy Market Attractiveness by End-User
Figure 63: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 64: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, By Country
Figure 65: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 66: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 67: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 68: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 69: Japan Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 70: Japan Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 71: China Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 72: China Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 73: India Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 74: India Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 75: Australia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 76: Australia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 77: New Zealand Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 78: New Zealand Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 79: Rest of Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 80: Rest of Asia Pacific Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 81: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 82: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 83: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 84: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 85: Latin America Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 86: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 87: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 88: Latin America Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 89: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 90: Brazil Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 91: Brazil Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 92: Mexico Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 93: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 94: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 95: Rest of Latin America Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 96: Latin America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 97: Latin America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 98: Latin America Cancer Immunotherapy Market Attractiveness by End-User
Figure 99: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 100: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 101: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 102: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 103: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 104: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 105: Saudi Arabia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 106: Saudi Arabia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 107: UAE Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 108: UAE Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 109: RSA Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 110: RSA Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 111: Rest of Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 112: Rest of Middle East & Africa Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 113: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 114: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 115: Middle East & Africa Cancer Immunotherapy Market Attractiveness by End-User

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Cancer Immunotherapy Market